Building the Foundation for a New Era of Quadruple Therapy in Heart Failure.
The serial development of treatments that improve morbidity and mortality in patients with chronic heart failure and reduced ejection fraction (HFrEF) is one the great success stories of cardiovascular therapeutics. Until recently, the combination of beta-blockers, reninangiotensin system inhibitors (angiotensin converting enzyme (ACE)-inhibitors or angiotensin receptor blockers (ARBs)), and mineralocorticoid receptor antagonists (MRAs) formed the foundation of "triple therapy" for heart failure. These agents, each of which provide clear benefits on mortality and morbidity in patients with HFrEF, collectively came to be termed "guideline directed medical therapy" (GDMT). This stable foundation of heart failure therapeutics was upended in 2014 by the stunning results of the PARADGIM-HF study, demonstrating substantial improvements in outcomes with the angiotensin receptor-neprilysin inhibitor (ARNi) sacubitril-valsartan above and beyond the benefits provided by the ACEinhibitor enalapril1. Now only a few years later, a remarkable dataset has emerged with the sodium-glucose cotransporter-2 inhibitors (SGLT2i) in heart failure. Initially, the diabetes cardiovascular outcome trials provided evidence of the role these agents in preventing incident HF in patients with type 2 diabetes. Finally, the recent publication of the primary results of the DAPA-HF demonstrated substantial benefits in outcomes on top of "triple therapy" for patients with chronic HFrEF, benefits that remarkably are similar in patients with and without diabetes2. So is it now time for "triple therapy" to evolve to "quadruple therapy" in patients with HFrEF?